Retro Biosciences is a pharmaceutical startup that wants to solve the world’s health problems with artificial intelligence (AI). The company intends to rely on AI to develop new drugs that benefit humanity. It’s seeking $1 billion in a new round of funding and attracting the interest of various investors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Chief among these investors is OpenAI CEO Sam Altman. He provided the company with its initial $180 million and partook in this latest fundraising round. Additionally, Retro Biosciences partnered with OpenAI to create a new AI model to handle drug research.
Retro Biosciences believes AI will allow for a quick turnaround when developing new medicines. It’s targeting approval and release of its first drug in the 2020s. For perspective, new drug companies normally take between 10 and 15 years to release their first products.
What Drugs Will Retro Biosciences Make?
Retro Biosciences’ first goal is to extend human life. It plans to do this via a drug that would turn normal cells into stem cells. This would allow the body to fight aging and potentially extend life by up to 10 years.
Retro Biosciences will build on this cell reprogramming to create drugs that treat other illnesses. One of its key focuses will be creating a treatment for Alzheimer’s disease. Another of its projects is medicine to revitalize blood and brain cells.
How to Invest in Retro Biosciences Stock?
Retro Biosciences is a private company, meaning retail traders don’t currently have a pathway to investing in it. Instead, they might consider investing in stocks held by OpenAI CEO Altman. His major investments include Reddit (RDDT), Airbnb (ABNB), Uber (UBER), and Asana (ASAN). Uber stands out among these stocks as a powerful investment candidate with a Strong Buy rating and $91.23 price target, representing a potential 34.34% upside for the shares.
